Theralase Technologies (CVE:TLT) Trading Down 2.6%

Theralase Technologies Inc. (CVE:TLT) traded down 2.6% during trading on Wednesday . The stock traded as low as C$0.19 and last traded at C$0.19. 378,865 shares were traded during mid-day trading, an increase of 164% from the average session volume of 143,671 shares. The stock had previously closed at C$0.20.

Theralase Technologies Price Performance

The company has a quick ratio of 3.40, a current ratio of 1.39 and a debt-to-equity ratio of 20.30. The firm has a 50 day moving average price of C$0.17 and a 200 day moving average price of C$0.18. The stock has a market cap of C$44.27 million, a P/E ratio of -9.25 and a beta of 1.59.

Theralase Technologies (CVE:TLT) last released its earnings results on Wednesday, March 27th. The company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$0.36 million during the quarter. On average, analysts forecast that Theralase Technologies Inc. will post -0.05 EPS for the current fiscal year.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.